Spyre Therapeutics (SYRE) Other financing activities (2017 - 2026)
Spyre Therapeutics' (SYRE) quarterly Other financing activities came in at $2.7 million in Q1 2026, up 1127.52% YoY from $218000.0 in Q1 2025, and up 271.87% on a QoQ basis from -$1.6 million in Q4 2025.
Spyre Therapeutics (SYRE) Other financing activities (2017 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 10 years of Other financing activities data on file, last reported at $2.7 million in Q1 2026.
- Quarterly Other financing activities rose 1127.52% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 158.93% YoY) and the FY2024 annual result came in at $1000.0, down 99.75% from the prior year.
- Other financing activities rose to $2.7 million in Q1 2026, from -$1.6 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $164.7 million in Q2 2024 to a low of -$162.9 million in Q3 2024.
- A 5-year average of $236000.0 and a median of $201000.0 in 2022 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 24288.89% in 2024, down 155211.43% in 2024.
- Tracing SYRE's Other financing activities over 5 years: stood at $38000.0 in 2022, then surged by 642.11% to $282000.0 in 2023, then plunged by 2299.29% to -$6.2 million in 2024, then surged by 74.9% to -$1.6 million in 2025, then soared by 271.87% to $2.7 million in 2026.
- The last three Other financing activities figures came in at $2.7 million (Q1 2026), -$1.6 million (Q4 2025), and $491000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 432.56 Mn |
| Jun 30, 2026 | 432.56 Mn |
| Mar 31, 2026 | 2.68 Mn |
| Mar 31, 2026 | 2.68 Mn |
| Dec 31, 2025 | -1.56 Mn |
| Dec 31, 2025 | -1.56 Mn |
| Sep 30, 2025 | 491,000.00 |
| Sep 30, 2025 | 491,000.00 |
| Jun 30, 2025 | 848,000.00 |
| Jun 30, 2025 | 848,000.00 |
| Mar 31, 2025 | 218,000.00 |
| Mar 31, 2025 | 218,000.00 |
| Dec 31, 2024 | -6.20 Mn |
| Dec 31, 2024 | -6.20 Mn |
| Sep 30, 2024 | -162.87 Mn |
| Sep 30, 2024 | -162.87 Mn |
| Jun 30, 2024 | 164.68 Mn |
| Jun 30, 2024 | 164.68 Mn |
| Mar 31, 2024 | 4.39 Mn |
| Mar 31, 2024 | 4.39 Mn |